Honkalammi J[au] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2009	1
2011	2
2012	1
2022	0

Page 1

Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Honkalammi J, et al. Clin Pharmacol Ther. 2012 May;91(5):846-55. doi: 10.1038/clpt.2011.313. Clin Pharmacol Ther. 2012. PMID: 22472994 Clinical Trial.

Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Honkalammi J, et al. Clin Pharmacol Ther. 2011 Apr;89(4):579-86. doi: 10.1038/clpt.2010.358. Epub 2011 Mar 2. Clin Pharmacol Ther. 2011. PMID: 21368757 Clinical Trial.

Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Honkalammi J, et al. Drug Metab Dispos. 2011 Oct;39(10):1977-86. doi: 10.1124/dmd.111.040931. Epub 2011 Jul 21. Drug Metab Dispos. 2011. PMID: 21778352 Clinical Trial.

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.

Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ. Backman JT, et al. Among authors: honkalammi j. Drug Metab Dispos. 2009 Dec;37(12):2359-66. doi: 10.1124/dmd.109.029728. Epub 2009 Sep 22. Drug Metab Dispos. 2009. PMID: 19773535 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results